Meeting
2022 ASCO Annual Meeting
Immune-related adverse effects of long-term PD-1/PD-L1 inhibtor treatment.
Authors
Sarah Kim
Stanford Health Care, Stanford, CA
Sarah Kim , A. Dimitrios Colevas , Stephanie Tse , Sandy On , Edna Cheung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2661)
DOI
10.1200/JCO.2022.40.16_suppl.2661
Abstract #
2661
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.
First Author: Peter Zang
First Author: Jeddeo Paul
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors.
First Author: Ryo Morikawa